Caprock Group, Inc. Abb Vie Inc. Transaction History

Caprock Group, Inc.

  • $2.71 Billion
  • Q3 2024

A detailed history of Caprock Group, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Caprock Group, Inc. holds 41,197 shares of ABBV stock, worth $7.42 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
41,197
Previous 37,450 10.01%
Holding current value
$7.42 Million
Previous $6.42 Million 26.65%
% of portfolio
0.3%
Previous 0.26%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
BUY
$163.84 - $199.33 $613,908 - $746,889
3,747 Added 10.01%
41,197 $8.14 Million
Q2 2024

Aug 06, 2024
BUY
$154.79 - $180.76 $2.38 Million - $2.78 Million
15,382 Added 69.7%
37,450 $6.42 Million
Q1 2024

Apr 29, 2024
BUY
$159.82 - $182.1 $399,230 - $454,885
2,498 Added 12.76%
22,068 $4.02 Million
Q4 2023

Jan 18, 2024
BUY
$137.6 - $154.97 $432,476 - $487,070
3,143 Added 19.13%
19,570 $3.03 Million
Q3 2023

Oct 18, 2023
BUY
$133.59 - $154.65 $38,340 - $44,384
287 Added 1.78%
16,427 $2.45 Million
Q2 2023

Aug 10, 2023
SELL
$132.51 - $164.9 $295,762 - $368,056
-2,232 Reduced 12.15%
16,140 $2.17 Million
Q1 2023

Apr 26, 2023
BUY
$144.61 - $166.54 $327,541 - $377,213
2,265 Added 14.06%
18,372 $2.93 Million
Q4 2022

Jan 23, 2023
SELL
$138.31 - $165.87 $301,377 - $361,430
-2,179 Reduced 11.92%
16,107 $0
Q3 2022

Nov 07, 2022
SELL
$134.21 - $153.93 $97,704 - $112,061
-728 Reduced 3.83%
18,286 $2.45 Million
Q2 2022

Jul 26, 2022
BUY
$137.62 - $174.96 $92,480 - $117,573
672 Added 3.66%
19,014 $2.91 Million
Q1 2022

Apr 12, 2022
SELL
$131.98 - $163.75 $161,939 - $200,921
-1,227 Reduced 6.27%
18,342 $2.97 Million
Q4 2021

Jan 18, 2022
SELL
$107.43 - $135.93 $356,130 - $450,607
-3,315 Reduced 14.49%
19,569 $2.65 Million
Q3 2021

Oct 07, 2021
BUY
$106.4 - $120.78 $314,199 - $356,663
2,953 Added 14.82%
22,884 $2.47 Million
Q2 2021

Aug 13, 2021
SELL
$105.21 - $117.21 $254,608 - $283,648
-2,420 Reduced 10.83%
19,931 $2.25 Million
Q1 2021

Apr 29, 2021
SELL
$102.3 - $112.62 $673,338 - $741,264
-6,582 Reduced 22.75%
22,351 $2.42 Million
Q4 2020

Jan 29, 2021
SELL
$80.49 - $108.67 $173,938 - $234,835
-2,161 Reduced 6.95%
28,933 $3.1 Million
Q3 2020

Oct 29, 2020
SELL
$85.91 - $100.83 $191,665 - $224,951
-2,231 Reduced 6.69%
31,094 $2.72 Million
Q2 2020

Aug 05, 2020
BUY
$73.37 - $98.18 $669,941 - $896,481
9,131 Added 37.74%
33,325 $3.27 Million
Q1 2020

Apr 28, 2020
BUY
$64.5 - $97.79 $229,684 - $348,230
3,561 Added 17.26%
24,194 $1.84 Million
Q4 2019

Feb 04, 2020
BUY
$72.13 - $90.25 $63,185 - $79,059
876 Added 4.43%
20,633 $1.83 Million
Q3 2019

Oct 31, 2019
BUY
$62.98 - $75.72 $386,193 - $464,315
6,132 Added 45.01%
19,757 $1.5 Million
Q2 2019

Jul 23, 2019
SELL
$65.7 - $83.98 $28,185 - $36,027
-429 Reduced 3.05%
13,625 $991,000
Q1 2019

Apr 12, 2019
BUY
$77.14 - $90.79 $106,376 - $125,199
1,379 Added 10.88%
14,054 $1.13 Million
Q4 2018

Jan 29, 2019
BUY
$77.85 - $96.01 $70,376 - $86,793
904 Added 7.68%
12,675 $1.17 Million
Q3 2018

Oct 17, 2018
SELL
$88.91 - $98.84 $37,342 - $41,512
-420 Reduced 3.45%
11,771 $1.11 Million
Q2 2018

Jul 23, 2018
SELL
$89.78 - $106.23 $384,976 - $455,514
-4,288 Reduced 26.02%
12,191 $1.13 Million
Q1 2018

Apr 23, 2018
SELL
$92.01 - $123.21 $137,186 - $183,706
-1,491 Reduced 8.3%
16,479 $1.56 Million
Q4 2017

Jan 17, 2018
SELL
$89.56 - $98.21 $179,299 - $196,616
-2,002 Reduced 10.02%
17,970 $1.82 Million
Q3 2017

Oct 23, 2017
BUY
$69.85 - $89.22 $1.4 Million - $1.78 Million
19,972
19,972 $1.78 Million

Others Institutions Holding ABBV

# of Institutions
3,853
Shares Held
1.25B
Call Options Held
16.8M
Put Options Held
12.2M
View Full List

About AbbVie Inc.

ABBV Quotes by TradingView
  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Caprock Group, Inc. Portfolio

Follow Caprock Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caprock Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Caprock Group, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email